Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Gregory Greenwood"'
Autor:
Sunil Babu, Guilia Antognoli, Elena Gutierréz, Yoshitaka Miyakawa, Moglie Le Quintrec, Jan Menne, David J. Kavanagh, Tatiana Kirsanova, Edwin K.S. Wong, Maria Vinogradova, Philip Campbell, Guillaume Favre, Michael Fischereder, Spero R. Cataland, Iino Fumie, Hermann Haller, Vladimir A. Dobronravov, Paramit Chowdhury, Guillaume Jeantet, Marie Scully, Sonia Boyer-Suavet, Thomas D. Barbour, Yosu Luque, Leonardo Caroti, Stephan Ortiz, Shashi K. Nagaraj, Cyril Garrouste, Masayoshi Okumi, Anja Gaeckler, Maria Cappuccilli, Chiu-Ching Huang, Anja Muhlfeld, Gema Ariceta, Gaetano La Manna, Eric Rondeau, Nils Heyne, Giorgia Comai, Natalia Ramos Terrada, Eric Goffin, Paola Rodriguez, Gregory Greenwood, Eugene Swenson, Barbara Seitz-Polski, Nilufer Broeders, Gowthami M. Arepally, Manuel Praga Terente, Marc Vallee, Johan Morelle, Siân V. Griffin, Nicole Lietar, Doyeun Oh, Theo Kasimatis, I-Ru Chen, Ulf Schönermarck, Susan Huang, Jin Seok Kim, Fiona G. Brown, François Provôt, Lino Cirami, Sung-Soo Yoon, Yahsou Delmas
Publikováno v:
Kidney international, Vol. 97, no.6, p. 1287-1296 (2020)
Kidney International
Kidney International, Nature Publishing Group, 2020, 97, pp.1287-1296. ⟨10.1016/j.kint.2020.01.035⟩
Kidney international, Vol. 97, no. 6, p. 1287-1296 (2020)
Kidney International
Kidney International, Nature Publishing Group, 2020, 97, pp.1287-1296. ⟨10.1016/j.kint.2020.01.035⟩
Kidney international, Vol. 97, no. 6, p. 1287-1296 (2020)
Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we evaluate the efficacy and safety of ravulizumab in adults with atypical h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645216d81d77d6e0af0d5786a23bf3d8
https://hdl.handle.net/2078.1/240266
https://hdl.handle.net/2078.1/240266